Nanomaterials for modulating the aggregation of β-amyloid peptides

Y Huang, Y Chang, L Liu, J Wang - Molecules, 2021 - mdpi.com
The aberrant aggregation of amyloid-β (Aβ) peptides in the brain has been recognized as
the major hallmark of Alzheimer's disease (AD). Thus, the inhibition and dissociation of Aβ …

Advanced nanomaterials for modulating Alzheimer's related amyloid aggregation

X Shao, C Yan, C Wang, C Wang, Y Cao, Y Zhou… - Nanoscale …, 2023 - pubs.rsc.org
Alzheimer's disease (AD) is a common neurodegenerative disease that brings about
enormous economic pressure to families and society. Inhibiting abnormal aggregation of Aβ …

Nanotechnological approaches for targeting amyloid-β aggregation with potential for neurodegenerative disease therapy and diagnosis

R Shukla, A Singh, M Handa, SJS Flora… - Drug Discovery …, 2021 - Elsevier
Neurodegenerative disorders can arise as a result of amyloid-β production and misfolding of
its protein. The complex anatomy of the brain and the unresolved mechanics of the central …

Current strategies for modulating Aβ aggregation with multifunctional agents

Z Du, M Li, J Ren, X Qu - Accounts of Chemical Research, 2021 - ACS Publications
Conspectus Alzheimer's disease (AD), as the primary cause of dementia, has seriously
affected millions of people worldwide and brought a very heavy financial and social burden …

Toward a rational design to regulate β-amyloid fibrillation for Alzheimer's disease treatment

X Han, G He - ACS chemical neuroscience, 2018 - ACS Publications
The last decades have witnessed a growing global burden of Alzheimer's disease (AD).
Evidence indicates that the onset and progression of AD is associated with β-amyloid (Aβ) …

Inhibiting protein aggregation by small molecule-based colloidal nanoparticles

K Debnath, AK Sarkar, NR Jana… - Accounts of materials …, 2021 - ACS Publications
Conspectus Protein aggregation is associated with different human diseases such as
Alzheimer's, Huntington's, Parkinson's, diabetes type II, and cataracts. Currently no effective …

Nanoparticle cluster depolymerizes and removes amyloid fibrils for Alzheimer's disease treatment

Q Feng, N Wang, X Zhang, Y Mei, R Fu, J Chen… - Nano Today, 2023 - Elsevier
Aberrant amyloid-β (Aβ) fibrillation is the key event in Alzheimer's disease (AD), the
depolymerization and removal of which are being pursued with enthusiasm. Herein, a …

Antiamyloidogenic chemical/biochemical-based designed nanoparticle as artificial chaperone for efficient inhibition of protein aggregation

N Pradhan, K Debnath, S Mandal, NR Jana… - …, 2018 - ACS Publications
Protein aggregation is linked to variety of neurodegenerative disorders and other diseases.
Current research involves understanding the mechanism of protein aggregation, inhibiting …

The membrane axis of Alzheimer's nanomedicine

Y Li, H Tang, N Andrikopoulos, I Javed… - Advanced …, 2021 - Wiley Online Library
Alzheimer's disease (AD) is a major neurological disorder impairing its carrier's cognitive
function, memory, and lifespan. While the development of AD nanomedicine is still nascent …

Nanocomposites inhibit the formation, mitigate the neurotoxicity, and facilitate the removal of β-amyloid aggregates in Alzheimer's disease mice

Y Zhao, J Cai, Z Liu, Y Li, C Zheng, Y Zheng… - Nano …, 2018 - ACS Publications
Alzheimer's disease (AD) is a progressive and irreversible brain disorder. Recent studies
revealed the pivotal role of β-amyloid (Aβ) in AD. However, there is no conclusive indication …